Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Moodys
Colorcon
Express Scripts
AstraZeneca

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR CILOSTAZOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Cilostazol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00048763 ↗ Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed Otsuka America Pharmaceutical Phase 4 2001-10-01 Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. When children with primary Raynaud's Phenomenon are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. Children with primary Raynaud's Phenomenon have no underlying systemic disease. The cause for their symptoms is unknown. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of primary Raynaud's episodes in juvenile patients.
NCT00048776 ↗ Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon Completed Otsuka America Pharmaceutical Phase 4 2001-10-01 Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears. Children with secondary Raynaud's Phenomenon have an underlying condition such as systemic lupus, scleroderma, or mixed connective tissue disease. When children with secondary Raynaud's are exposed to chilly or cold conditions from weather, cold temperatures, or even holding cold items from the refrigerator, their fingers may become cold, numb, hurt, and/or turn purple or white. The investigational drug, Pletal(cilostazol), which has been approved for other conditions, inhibits the ability of one type of blood cell, platelets, to form blood clots, and also widens narrowed blood vessels. It has been used in a variety of other conditions in which blood flow is decreased. This study will test the safety and effectiveness Pletal(cilostazol) to lessen the severity of the symptoms and decrease the number of secondary Raynaud's episodes in juvenile patients.
NCT00130039 ↗ Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed Korea Otsuka International Asia Arab Phase 4 2005-08-01 This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery). They will be randomly assigned into cilostazol group or clopidogrel group. Every patients will take 100mg of aspirin a day additionally. The primary outcome variable of this study is Progression rate of symptomatic intracranial stenosis on magnetic resonance angiogram (MRA).
NCT00130039 ↗ Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed Asan Medical Center Phase 4 2005-08-01 This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery). They will be randomly assigned into cilostazol group or clopidogrel group. Every patients will take 100mg of aspirin a day additionally. The primary outcome variable of this study is Progression rate of symptomatic intracranial stenosis on magnetic resonance angiogram (MRA).
NCT00132743 ↗ Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Unknown status National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2007-02-01 The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.
NCT00132743 ↗ Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Unknown status Joselyn Cerezo, MD Phase 3 2007-02-01 The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.
NCT00202020 ↗ Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke Completed Zhejiang Otsuka Pharmaceutical Co., Ltd. Phase 3 2004-05-01 The study design is subject to relevant SFDA regulations about clinical trials. This indication was approved in Japan in 2003. From the end of May 2004 to the end of Dec. 2004, 720 patients with previous cerebral infarction(see the inclusion criteria) were enrolled in to the study and received one of the two treatment regimens, Cilostazol or Aspirin, the ratio of patient number of each group is 1:1. For each patient, the chance of entering either of these two groups is the same. The treatment will continue till the end of 2005. During the treatment period, patients will be observed concerning some certain events, mainly reoccurrence of stroke. If the patient experiences reoccurrence of stroke, or other event that the doctors think it is not appropriate to continue the study medication, this patient would stop the treatment. Patients were also required to take MRI head scan before entering the study and on completion of the treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cilostazol

Condition Name

Condition Name for Cilostazol
Intervention Trials
Healthy 10
Peripheral Arterial Disease 9
Intermittent Claudication 9
Coronary Artery Disease 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cilostazol
Intervention Trials
Peripheral Arterial Disease 23
Peripheral Vascular Diseases 17
Intermittent Claudication 14
Infarction 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cilostazol

Trials by Country

Trials by Country for Cilostazol
Location Trials
United States 80
Korea, Republic of 68
Russian Federation 30
China 16
Japan 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cilostazol
Location Trials
Missouri 7
California 5
Ohio 4
New York 4
New Jersey 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cilostazol

Clinical Trial Phase

Clinical Trial Phase for Cilostazol
Clinical Trial Phase Trials
Phase 4 58
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 54
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cilostazol
Clinical Trial Phase Trials
Completed 84
Unknown status 21
Recruiting 11
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cilostazol

Sponsor Name

Sponsor Name for Cilostazol
Sponsor Trials
Korea Otsuka Pharmaceutical Co., Ltd. 16
Seoul National University Hospital 6
Otsuka Pharmaceutical Co., Ltd. 6
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cilostazol
Sponsor Trials
Other 154
Industry 63
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Moodys
AstraZeneca
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.